Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from LadRx (LADX).
On June 3, 2024, LadRx Corporation ended its exclusive worldwide license agreement for aldoxorubicin with NantCell, clearing all obligations except potential negotiations for LadRx to buy remaining aldoxorubicin inventory. Concurrently, LadRx amended its royalty agreement with XOMA, outlining new royalty payments if LadRx commercializes aldoxorubicin itself or licenses it to a third party. These strategic moves could reshape LadRx’s future revenue streams and impact investor outlook on the company’s market position.
Learn more about LADX stock on TipRanks’ Stock Analysis page.